Table 3 Types of cardiotoxicity

From: Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Type I Cardiotoxicity

Type II Cardiotoxicity

• Early Onset

• Late Onset

• Myocardial damage

• Myocardial Dysfunction

• Permanent / Irreversible

• Reversible in nature

• Dose-dependent effects

• Cumulative Dose-independent effects

• Greater association with Cardiac Dysfunction and Clinical HF

• Increased loss of contractility and less myocyte death

• Typically, with Anthracyclines (Doxorubicin), Alkylating Agents Taxanes, Topoisomerase Inhibitors, Antimetabolites

• Typically, with Trastuzumab, Bevacizumab, and other Tyrosine Kinase Inhibitors, Immunomodulatory drugs, and Proteasome inhibitors but patients may develop type I cardiotoxicity in the long run

Back to article page